Trial Profile
The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 07 Jun 2021 Planned End Date changed from 1 Jan 2031 to 2 Jan 2031.
- 07 Jun 2021 Planned primary completion date changed from 1 Jan 2031 to 2 Jan 2031.
- 21 Sep 2020 Planned primary completion date changed from 31 Jul 2030 to 1 Jan 2031.